HCV ANTIVIRAL TESTING IN CHIMPANZEES

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 大约2%的美国人口长期感染丙型肝炎病毒(丙型肝炎病毒)。慢性丙型肝炎病毒感染会导致严重的肝脏疾病，包括大约20%的感染者中的肝硬变和肝癌。目前的干扰素和利巴韦林治疗在大多数病例中不能导致病毒清除。开发改进的抗病毒策略来治疗丙型肝炎病毒慢性感染对于控制这种疾病是至关重要的。本研究的目的是测试一系列小分子丙型肝炎病毒复制抑制剂对慢性感染丙型肝炎病毒的黑猩猩的疗效。这项研究检测了几种不同类别的抑制剂的抗病毒活性，并在PK和疗效研究中对每一类药物进行了检测

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Approximately 2% of the U.S. population is chronically infected with hepatitis C virus (HCV). Chronic HCV infections result in significant liver disease, including cirrhosis and liver cancer in approximately 20% of infected individuals. The current therapy of interferon and ribavirin does not result in viral clearance in the majority of cases. The development of improved antiviral strategies to treat HCV chronic infection is essential for the control of this disease. The objective of this study is to test a series of small molecule antiviral inhibitors of HCV replication for efficacy in chimpanzees chronically infected with HCV. The study has examined antiviral activity from several different classes of inhibitors, and each of the classes has been examined in both PK and efficacy studies